polypharmacy

When is antipsychotic polypharmacy supported by research evidence? Implications for QI.

Gören JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, et al.. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf. 2008;34(10):571-82. PubMed PMID: 18947117.

Problems of polypharmacy.

Herxheimer A, McGettigan P. Problems of polypharmacy. BMJ. 2013;347:f7500. doi: 10.1136/bmj.f7500. PubMed PMID: 24366533.

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

Essock SM, Schooler NR, Stroup ST, McEvoy JP, Rojas I, Jackson C, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168(7):702-8. doi: 10.1176/appi.ajp.2011.10060908. PubMed PMID: 21536693.

Safety and tolerability of antipsychotic polypharmacy.

Gallego JA, Nielsen J, De Hert M, Kane JM, Correll CU. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11(4):527-42. doi: 10.1517/14740338.2012.683523. PubMed PMID: 22563628; PubMed Central PMCID: PMC3384511.